Novo Nordisk Strikes Second Licensing Deal Since Frosty Capital-Markets Day

3-line summary

• Novo Nordisk struck its second licensing deal since a frosty capital-markets day, according to a MarketWatch report.
• This follows an earlier report of a $2.6 billion drug deal Novo Nordisk signed with Hengrui Pharma.

This summary is our own processing of the source article; see the source link below for full context.